Received Mar 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5G23D | — |
patient under 4 years of age received Kinrix; patient under 4 years of age received Kinrix as their their 1st DTAP and IPV dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 2-month-old male patient who received DTPa-IPV (Kinrix) (batch number 5G23D, expiry date 21-AUG-2026) for prophylaxis. On 05-MAR-2025, the patient received the 1st dose of Kinrix. On 05-MAR-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: patient under 4 years of age received Kinrix) and inappropriate schedule of product administration (Verbatim: patient under 4 years of age received Kinrix as their their 1st DTAP and IPV dose). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of product administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-MAR-2025 Office manager reported patient under 4 years of age received Kinrix as their 1st DTAP and IPV dose, which led to an inappropriate age at vaccine administration and inappropriate schedule of product administration.